Skip to main navigation

Top Menu

About Us
Our Science
Pipeline
Partnering
Investors & Media
Careers
Contact

Investors & Media

Press Releases

Year

Entasis Therapeutics Appoints David Meek as Chairman of the Board

Jun 24, 2019

Entasis Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference

Jun 18, 2019

Entasis Therapeutics Announces Initial ETX0282 Phase 1 Results

Jun 13, 2019

Entasis Therapeutics Announces Oral and Poster Presentations of its Pathogen-Targeted Antibiotic Clinical Programs at ASM Microbe 2019

Jun 10, 2019

Entasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update

May 14, 2019

Entasis Therapeutics to Participate in the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit

Apr 30, 2019

Entasis Therapeutics Strengthens Leadership Team with Appointment of Eric Kimble as Chief Commercial Officer

Apr 23, 2019

Entasis Therapeutics Announces the Appointment of Elizabeth Keiley as General Counsel

Apr 16, 2019

Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019

Apr 10, 2019

Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections

Apr 04, 2019

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Next page
Last page

Displaying 21 - 30 of 68

Toolkit

Print page
RSS Feeds
Email Alerts
Search

Investor Relations

Corporate Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
SEC Filings
Corporate Governance
Investor Resources

"Antibiotic resistance is a worldwide problem that is constantly growing. New forms of resistance can spread quickly and across continents. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections."

— Ruben Tommasi, Chief Scientific Officer

©2020 Entasis Therapeutics Inc.

Terms of Use | Privacy Policy